ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.14 USD
+0.02 (0.94%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.16 +0.02 (0.93%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
ProQR (PRQR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.26 | $6.00 | $1.80 | 100.94% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for ProQR comes to $4.26. The forecasts range from a low of $1.80 to a high of $6.00. The average price target represents an increase of 100.94% from the last closing price of $2.12.
Analyst Price Targets (5 )
Broker Rating
ProQR currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PRQR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/11/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
8/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
4/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/8/2024 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
1/24/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 6 |
Average Target Price | $4.26 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.12 |